Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV
Authors:
- 1 March 2025
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 10 (3) , 254
Abstract
Importance: In a mechanistic substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) randomized clinical trial, pitavastatin reduced noncalcified plaque (NCP) volume, but specific protein and gene pathways contributing to changes in coronary plaque remain unknown.Objective: To use targeted discovery proteomics and transcriptomics approaches to interrogate biological pathways beyond low-density lipoprotein cholesterol (LDL-C), relating statin outcomes to reduce NCP volume and promote plaque stabilization among people with HIV (PWH).Design, Setting, and Participants: This was a post hoc analysis of the double-blind, placebo-controlled, REPRIEVE randomized clinical trial. Participants underwent coronary computed tomography angiography (CTA), plasma protein analysis, and transcriptomic analysis at baseline and 2-year follow-up. The trial enrolled PWH from April 2015 to February 2018 at 31 US research sites. PWH without known cardiovascular diseases taking antiretroviral therapy and with low to moderate 10-year cardiovascular risk were eligible. Data analyses were conducted from October 2023 to February 2024.Intervention: Oral pitavastatin calcium, 4 mg per day.Main Outcomes and Measures: Relative change in plasma proteomics, transcriptomics, and noncalcified plaque volume among those receiving treatment vs placebo.Results: Among 558 individuals (mean [SD] age, 51 [6] years; 455 male [82%]) included in the proteomics assessment, 272 (48.7%) received pitavastatin and 286 (51.3%) received placebo. After adjusting for false discovery rates, pitavastatin increased abundance of procollagen C-endopeptidase enhancer 1 (PCOLCE), neuropilin 1 (NRP-1), major histocompatibility complex class I polypeptide-related sequence A (MIC-A) and B (MIC-B), and decreased abundance of tissue factor pathway inhibitor (TFPI), tumor necrosis factor ligand superfamily member 10 (TRAIL), angiopoietin-related protein 3 (ANGPTL3), and mannose-binding protein C (MBL2). Among these proteins, the association of pitavastatin with PCOLCE (a rate-limiting enzyme of collagen deposition) was greatest, with an effect size of 24.3% (95% CI, 18.0%-30.8%; P < .001). In a transcriptomic analysis, individual collagen genes and collagen gene sets showed increased expression. Among the 195 individuals with plaque at baseline (88 [45.1%] taking pitavastatin, 107 [54.9%] taking placebo), changes in NCP volume were most strongly associated with changes in PCOLCE (%change NCP volume/log2-fold change = −31.9%; 95% CI, −42.9% to −18.7%; P < .001), independent of changes in LDL-C level. Increases in PCOLCE related most strongly to change in the fibro-fatty (2-fold change = −38.5%; 95% CI, −58.1% to −9.7%; P = .01) with a directionally opposite, although nonsignificant, increase in calcified plaque (%change calcified volume/log2-fold change = 34.4%; 95% CI, −7.9% to 96.2%; P = .12).Conclusions and Relevance: Results of this secondary analysis of the REPRIEVE randomized clinical trial suggest that PCOLCE may be associated with the atherosclerotic plaque stabilization effects of statins by promoting collagen deposition in the extracellular matrix transforming vulnerable plaque phenotypes to more stable coronary lesions.Trial Registration: ClinicalTrials.gov Identifier: NCT02344290Keywords
This publication has 37 references indexed in Scilit:
- Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIVJAMA Cardiology, 2024
- Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIVEBioMedicine, 2023
- Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque CompositionJAMA Cardiology, 2021
- Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular PreventionJAMA Network Open, 2021
- Decrease in LDL-C is associated with decrease in all components of noncalcified plaque on coronary CTAAtherosclerosis, 2019
- Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersAmerican Heart Journal, 2019
- Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)American Heart Journal, 2019
- HIV Infection and the Risk of Acute Myocardial InfarctionJAMA Internal Medicine, 2013
- Lipid-Related Markers and Cardiovascular Disease PredictionJAMA, 2012
- Mannan-binding lectin deficiency — Good news, bad news, doesn't matter?Clinical Immunology, 2012